Abstract
Prevalence estimates of depression in AD vary greatly across studies, and a reliable result is crucial for further interventions. A systematic review and meta-analysis was conducted to identify the prevalence of depression in AD patients. We searched PubMed and Embase, followed by data extraction, quality assessment, prevalence estimates and subgroup analyses. A total of 63 studies were included in the review. The prevalences of depression were 12.7% (CI, 8.8-17.8) and 42% (CI, 38-45) according to the DSM criteria for major depression and the specific criteria for dementia respectively. Subgroup analyses stratified by case identification showed that the prevalences of population-based stud ies were 5% (CI: 2-15) and 35% (CI: 29-41) according to the DSM criteria and the specific criteria respectively, while those of single source were 17% (CI: 11-25) and 43% (CI: 37-49). Subgroup analyses stratified by MMSE score revealed that the prevalences of severe AD were 8% (CI: 5-15) and 48% (CI: 41-54) according to the DSM criteria and the specific criteria respectively, while those of mild AD were 14% (CI: 8-24) and 40% (CI: 32- 47). In conclusion, the prevalence of depression according to the DSM criteria was lower than that of the specific criteria. Prevalence estimates conducted in population-based studies were lower compared with those in single-source studies irrespective of the screening tools. Patients with severe AD tended to have higher prevalence of depression according to the specific criteria, while the trend was opposite according to the DSM criteria. Thus, different settings and diagnostic approaches should be taken into account before estimates of depression and further interventions.
Keywords: Alzheimer’s disease, depression, epidemiology, meta-analysis, prevalence, systematic review.
Current Alzheimer Research
Title:The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Volume: 12 Issue: 2
Author(s): Song Chi, Chong Wang, Teng Jiang, Xi-Chen Zhu, Jin-Tai Yu and Lan Tan
Affiliation:
Keywords: Alzheimer’s disease, depression, epidemiology, meta-analysis, prevalence, systematic review.
Abstract: Prevalence estimates of depression in AD vary greatly across studies, and a reliable result is crucial for further interventions. A systematic review and meta-analysis was conducted to identify the prevalence of depression in AD patients. We searched PubMed and Embase, followed by data extraction, quality assessment, prevalence estimates and subgroup analyses. A total of 63 studies were included in the review. The prevalences of depression were 12.7% (CI, 8.8-17.8) and 42% (CI, 38-45) according to the DSM criteria for major depression and the specific criteria for dementia respectively. Subgroup analyses stratified by case identification showed that the prevalences of population-based stud ies were 5% (CI: 2-15) and 35% (CI: 29-41) according to the DSM criteria and the specific criteria respectively, while those of single source were 17% (CI: 11-25) and 43% (CI: 37-49). Subgroup analyses stratified by MMSE score revealed that the prevalences of severe AD were 8% (CI: 5-15) and 48% (CI: 41-54) according to the DSM criteria and the specific criteria respectively, while those of mild AD were 14% (CI: 8-24) and 40% (CI: 32- 47). In conclusion, the prevalence of depression according to the DSM criteria was lower than that of the specific criteria. Prevalence estimates conducted in population-based studies were lower compared with those in single-source studies irrespective of the screening tools. Patients with severe AD tended to have higher prevalence of depression according to the specific criteria, while the trend was opposite according to the DSM criteria. Thus, different settings and diagnostic approaches should be taken into account before estimates of depression and further interventions.
Export Options
About this article
Cite this article as:
Chi Song, Wang Chong, Jiang Teng, Zhu Xi-Chen, Yu Jin-Tai and Tan Lan, The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis, Current Alzheimer Research 2015; 12 (2) . https://dx.doi.org/10.2174/1567205012666150204124310
DOI https://dx.doi.org/10.2174/1567205012666150204124310 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 1
Recent Patents on Cardiovascular Drug Discovery Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prion Disease: A Deadly Disease for Protein Misfolding
Current Pharmaceutical Biotechnology A Resurrection of 7-MEOTA: A Comparison with Tacrine
Current Alzheimer Research Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Properties of CA3 Dendritic Excrescences in Alzheimers Disease
Current Alzheimer Research Amino Thiols, Detoxification and Oxidative Stress in Pre-Eclampsia and Other Disorders of Pregnancy
Current Pharmaceutical Design Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents
Current Topics in Medicinal Chemistry Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets